Desogestrel

證據等級: L5

預測適應症: 10 個

Desogestrel: Evaluation Incomplete — No Predicted Indications Available

One-Sentence Summary

Desogestrel (DB00304) is a synthetic progestogen used in oral contraceptives and hormone-based therapies. The current Evidence Pack contains no TxGNN predicted indications for this drug, and critical data including original indications, mechanism of action, and safety information are unavailable. A complete repurposing evaluation cannot be conducted until these data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A (no prediction to evaluate)
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why This Evaluation Cannot Proceed

The Evidence Pack for Desogestrel is missing two categories of foundational data required for a repurposing assessment:

No TxGNN Predictions. The predicted_indications array is empty. This may indicate that Desogestrel was not successfully embedded in the knowledge graph, that its node lacked sufficient connections to generate high-confidence predictions, or that the prediction pipeline encountered an upstream error. Without a target indication, no clinical or mechanistic analysis can follow.

No Mechanism of Action (MOA) Data. Although a DrugBank query returned one result (query log entry #3), the MOA field was not populated in the Evidence Pack. Desogestrel is a third-generation synthetic progestogen that binds progesterone receptors and suppresses ovulation; however, citing this from general knowledge rather than the structured data source would not meet the evidence standards required for a repurposing report.

No Original Indications Recorded. The original_indications array is empty, making it impossible to characterise the drug's approved therapeutic context or establish a mechanistic bridge to any new indication.

New Zealand Market Information

Desogestrel has no registered authorisations in the New Zealand database as of the data cutoff (2026-04-20).

Item	Status
Market status	Not marketed
Total authorisations	0
Available dosage forms	None on record

Safety Considerations

Please refer to the package insert for safety information.

No safety data (warnings, contraindications, or drug interactions) was returned in this Evidence Pack. A TFDA package insert query was logged as successful (query log entry #4), but the structured output was not populated. DDI query returned no results (query log entry #2).

Conclusion and Next Steps

Decision: Hold

Rationale: The absence of TxGNN predictions means there is no repurposing candidate to evaluate. All downstream sections — clinical trial evidence, literature review, mechanism analysis, and cytotoxicity assessment — depend on a predicted indication existing. Proceeding without one would produce a report with no clinical substance.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for DB00304 and confirm whether the drug node exists in the knowledge graph and has qualifying edges.
Populate MOA from DrugBank API — the query returned a record (result_count: 1) but the field was not extracted; re-parse the DrugBank response to retrieve mechanism, pharmacology, and drug categories.
Extract TFDA package insert content — the insert query was logged as successful but no warnings or contraindications were populated; re-parse the PDF to extract structured safety data (DG001, Blocking severity).
Confirm original indications — retrieve approved indication text from either the DrugBank record or regulatory sources so the drug's therapeutic baseline can be established.
Once the above are resolved, re-generate the Evidence Pack (target: v5) and resubmit for full evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.